29 abril 2014

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Structural Heart Disease. Relationship Between Valve Calcification and Long-Term Results of Percutaneous Mitral Commissurotomy for Rheumatic Mitral Stenosis

Claire Bouleti, MD, PhD, Bernard Iung, MD, Dominique Himbert, MD, David Messika-Zeitoun, MD, PhD, Eric Brochet, MD, Eric Garbarz, MD, Bertrand Cormier, MD and Alec Vahanian, MD

Background: Indications of percutaneous mitral commissurotomy (PMC) remain debated in calcific mitral stenosis. We analyzed long-term results of PMC for calcific mitral stenosis and the factors associated with late functional results.

27 mayo 2014

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Congenital Heart Disease. Use and Performance of the Melody Transcatheter Pulmonary Valve in Native and Postsurgical, Nonconduit Right Ventricular Outflow Tracts

Jeffery J. Meadows, MD, Phillip M. Moore, MD, Darren P. Berman, MD, John P. Cheatham, MD, Sharon L. Cheatham, NP, PhD, Diego Porras, MD, Matthew J. Gillespie, MD, Jonathan J. Rome, MD, Evan M. Zahn, MD and Doff B. McElhinney, MD

Background: Melody Transcatheter Pulmonary Valve (TPV) replacement therapy represents an important advance in congenital cardiovascular interventions. The off-label extension of the Melody TPV to patients with nonconduit outflow tracts (right ventricular outflow tract [RVOT]) has the potential to vastly expand the population of patients eligible to benefit from nonsurgical restoration of RVOT function. However, knowledge on the performance of the Melody TPV in this setting is limited.

20 mayo 2014

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Coronary Interventions. Biolimus-Eluting Stents With Biodegradable Polymer Versus Bare-Metal Stents in Acute Myocardial Infarction. Two-Year Clinical Results of the COMFORTABLE AMI Trial

Lorenz Räber, MD, Henning Kelbæk, MD, Masanori Taniwaki, MD, Miodrag Ostojic, MD, Dik Heg, MSc, Andreas Baumbach, MD, Clemens von Birgelen, MD, PhD, Marco Roffi, MD, David Tüller, MD, Thomas Engstrøm, MD, Aris Moschovitis, MD, Giovanni Pedrazzini, MD, Peter Wenaweser, MD, Ran Kornowski, MD, Klaus Weber, MD, Thomas F. Lüscher, MD, Christian M. Matter, MD, Bernhard Meier, MD, Peter Jüni, MD and Stephan Windecker, MD for the COMFORTABLE AMI Trial Investigators

Background: This study sought to determine whether the 1-year differences in major adverse cardiac event between a stent eluting biolimus from a biodegradable polymer and bare-metal stents (BMSs) in the COMFORTABLE trial (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) were sustained during long-term follow-up.

06 mayo 2014

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Coronary Interventions. Long-Term Clinical Outcomes After Everolimus- and Sirolimus-Eluting Coronary Stent Implantation. Final 3-Year Follow-Up of the Randomized Evaluation of Sirolimus-Eluting Versus Everolimus-Eluting Stent Trial

Hiroki Shiomi, MD, Ken Kozuma, MD, Takeshi Morimoto, MD, Keiichi Igarashi, MD, Kazushige Kadota, MD, Kengo Tanabe, MD, Yoshihiro Morino, MD, Takashi Akasaka, MD, Mitsuru Abe, MD, Satoru Suwa, MD, Toshiya Muramatsu, MD, Masakazu Kobayashi, MD, Kazuoki Dai, MD, Koichi Nakao, MD, Masaaki Uematsu, MD, Yasuhiro Tarutani, MD, Kenshi Fujii, MD, Charles A. Simonton, MD and Takeshi Kimura, MD on behalf of the RESET Investigators*

Background: Long-term clinical outcomes of everolimus-eluting stent (EES) compared with sirolimus-eluting stent (SES) have not been evaluated fully yet, especially whether EES implantation could positively affect late adverse events reported after SES implantation occurring >1 year.

03 junio 2014

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Coronary Interventions. Long-Term Safety of an Everolimus-Eluting Bioresorbable Vascular Scaffold and the Cobalt-Chromium XIENCE V Stent in a Porcine Coronary Artery Model

Fumiyuki Otsuka, MD, PhD, Erica Pacheco, MS, Laura E.L. Perkins, DVM, PhD, Jennifer P. Lane, BS, Qing Wang, MD, PhD, Marika Kamberi, PhD, Michael Frie, BS, Jin Wang, PhD, Kenichi Sakakura, MD, Kazuyuki Yahagi, MD, Elena Ladich, MD, Richard J. Rapoza, PhD, Frank D. Kolodgie, PhD and Renu Virmani, MD

Background: The Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb) has shown promising clinical results; however, only limited preclinical data have been published. We sought to investigate detailed pathological responses to the Absorb versus XIENCE V (XV) in a porcine coronary model with duration of implant extending from 1 to 42 months.

01 junio 2014

RADIOLOGY. Coronary Artery Disease: Diagnostic Accuracy of CT Coronary Angiography—A Comparison of High and Standard Spatial Resolution Scanning

Gianluca Pontone, MD, Erika Bertella, MD, Saima Mushtaq, MD, Monica Loguercio, MD, Sarah Cortinovis, MD, Andrea Baggiano, MD, Edoardo Conte, MD, Andrea Annoni, MD, Alberto Formenti, MD, Virginia Beltrama, Andrea Igoren Guaricci, MD, Daniele Andreini, MD, PhD

To compare the image quality, evaluability, diagnostic accuracy, and radiation exposure of high-spatial-resolution (HR, 0.23-mm) computed tomographic (CT) coronary angiography with standard spatial resolution (SR, 0.625-mm) 64-section imaging in patients at high risk for coronary artery disease (CAD) by using invasive coronary angiography (ICA) as the reference method.

01 junio 2014

RADIOLOGY. Collateral Vessel Opacification with CT in Patients with Coronary Total Occlusion and Its Relationship with Downstream Myocardial Infarction

Jiayin Zhang, MD, Yuehua Li, MD, Minghua Li, MD, Jingwei Pan, MD, Zhigang Lu, MD

To assess the correlation between the filling pattern of distal coronary vessels in patients with chronic total occlusion (CTO) observed at coronary computed tomographic (CT) angiography and the extent of downstream myocardial infarction (MI).

01 junio 2014

RADIOLOGY. Potential Predictors of Side-Branch Occlusion in Bifurcation Lesions after Percutaneous Coronary Intervention: A Coronary CT Angiography Study

Jin Joo Park, MD, Eun Ju Chun, MD, Young-Seok Cho, MD, PhD, Il-Young Oh, MD, Chang-Hwan Yoon, MD, Jung-Won Suh, MD, Sang Il Choi, MD, Tae-Jin Youn, MD, Bon-Kwon Koo, MD, In-Ho Chae, MD, Dong-Ju Choi, MD

To identify potential predictors of side-branch occlusion after main-vessel (artery) stent implantation in bifurcation lesions by using coronary computed tomography (CT) angiography.

01 abril 2014

JACC. 4-Year Clinical Outcomes and Predictors of Repeat Revascularization in Patients Treated With New-Generation Drug-Eluting Stents. A Report From the RESOLUTE All-Comers Trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention)

Masanori Taniwaki, MD∗; Giulio G. Stefanini, MD∗; Sigmund Silber, MD, PhD†; Gert Richardt, MD‡; Pascal Vranckx, MD§; Patrick W. Serruys, MD, PhD‖; Pawel E. Buszman, MD¶; Henning Kelbaek, MD#; Stephan Windecker, MD∗

Objectives: The aim of the study was to investigate 4-year outcomes and predictors of repeat revascularization in patients treated with the Resolute zotarolimus-eluting stent (R-ZES) (Medtronic, Minneapolis, Minnesota) and XIENCE V everolimus-eluting stent (EES) (Abbott Vascular, Abbott Park, Illinois) in the RESOLUTE (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention) All-Comers trial.

01 abril 2014

JACC. Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Patients With Stable Coronary Artery Disease. Results of the SWAP-2 Study (Switching Anti Platelet-2)

Dominick J. Angiolillo, MD, PhD∗; Nicholas Curzen, BM (Hons), PhD†; Paul Gurbel, MD‡; Paul Vaitkus, MD§; Fred Lipkin, PharmD§; Wei Li, PhD§; Joseph A. Jakubowski, PhD‖; Marjorie Zettler, PhD, MPH‖; Mark B. Effron, MD‖; Dietmar Trenk, PhD¶

Objectives: The goal of this study was to evaluate the pharmacodynamic effects of switching patients from ticagrelor to prasugrel.

01 abril 2014

JACC. Ticagrelor Effects on Myocardial Infarction and the Impact of Event Adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) Trial

Kenneth W. Mahaffey, MD∗; Claes Held, MD, PhD‡; Daniel M. Wojdyla, MS∗; Stefan K. James, MD, PhD‡; Hugo A. Katus, MD§; Steen Husted, MD, DSc‖; Philippe Gabriel Steg, MD¶; Christopher P. Cannon, MD††; Richard C. Becker, MD∗; Robert F. Storey, MD, DM‡‡; Nardev S. Khurmi, MD§§; José C. Nicolau, MD, PhD‖‖; Cheuk-Man Yu, MD¶¶; Diego Ardissino, MD##; Andrzej Budaj, MD, PhD∗∗∗; Joao Morais, MD†††; Debra Montgomery∗; Anders Himmelmann, MD, PhD‡‡‡; Robert A. Harrington, MD†; Lars Wallentin, MD, PhD‡

Objectives: This study sought to report the treatment effect of ticagrelor on myocardial infarction (MI) and the strategy for and impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial.

01 abril 2014

JACC. New-Onset Atrial Fibrillation After Aortic Valve Replacement. Comparison of Transfemoral, Transapical, Transaortic, and Surgical Approaches

Tanyanan Tanawuttiwat, MD∗; Brian P. O´Neill, MD†; Mauricio G. Cohen, MD∗; Orawee Chinthakanan, MD‡; Alan W. Heldman, MD∗; Claudia A. Martinez, MD∗; Carlos E. Alfonso, MD∗; Raul D. Mitrani, MD∗; Conrad J. Macon, MD§; Roger G. Carrillo, MD‖; Donald B. Williams, MD‖; William W. O´Neill, MD¶; Robert J. Myerburg, MD∗

Objectives: This study sought to determine the incidence of new-onset atrial fibrillation (AF) associated with different methods of isolated aortic valve replacement (AVR)—transfemoral (TF), transapical (TA), and transaortic (TAo) catheter-based valve replacement and conventional surgical approaches.

01 abril 2014

JACC. Sex-Related Differences in Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis. Insights From the PARTNER Trial (Placement of Aortic Transcatheter Valve)

Mathew Williams, MD∗; Susheel K. Kodali, MD∗; Rebecca T. Hahn, MD∗; Karin H. Humphries, DS, DSc†; Vuyisile T. Nkomo, MD‡; David J. Cohen, MD, MS§; Pamela S. Douglas, MD||; Michael Mack, MD¶; Thomas C. McAndrew, MS#; Lars Svensson, MD, PhD∗∗; Vinod H. Thourani, MD††; E. Murat Tuzcu, MD∗∗; Neil J. Weissman, MD‡‡; Ajay J. Kirtane, MD, SM∗; Martin B. Leon, MD∗

Objectives: This study sought to examine sex-specific differences in outcomes after surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR) in high-risk patients with severe aortic stenosis.

01 abril 2014

JACC. A Prospective Randomized Trial of Everolimus-Eluting Stents Versus Bare-Metal Stents in Octogenarians. The XIMA Trial (Xience or Vision Stents for the Management of Angina in the Elderly)

Adam de Belder, MD∗; Jose M. de la Torre Hernandez, MD, PhD†; Ramon Lopez-Palop, PhD‡; Peter O´Kane, MD§; Felipe Hernandez Hernandez, MD‖; Julian Strange, MD¶; Federico Gimeno, PhD#; James Cotton, MD∗∗; Jose F. Diaz Fernandez, MD††; Pilar Carrillo Saez, PhD‡; Martyn Thomas, MD‡‡; Eduardo Pinar, PhD§§; Nick Curzen, PhD‖‖; Jose A. Baz, MD¶¶; Nina Cooter, RCN∗; Inigo Lozano, PhD##; Nicola Skipper, RCN∗; Derek Robinson, PhD∗∗∗; David Hildick-Smith, MD∗

Objectives: The aim of this study was to determine whether drug-eluting stents (DES) are superior to bare-metal stents (BMS) in octogenarian patients with angina.

01 abril 2014

JACC. A Randomized Comparison of Drug-Eluting Balloon Versus Everolimus-Eluting Stent in Patients With Bare-Metal Stent–In-Stent Restenosis. The RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting Balloon vs. Everolimus-eluting Stent)

Fernando Alfonso, MD∗; Maria Jose Pérez-Vizcayno, MD†; Alberto Cárdenas, MD†; Bruno García del Blanco, MD‡; Bernhard Seidelberger, MD∗; Andrés Iñiguez, MD§; Manuel Gómez-Recio, MD‖; Mónica Masotti, MD¶; M. Teresa Velázquez, MD#; Juan Sanchís, MD∗∗; Arturo García-Touchard, MD††; Javier Zueco, MD‡‡; Armando Bethencourt, MD§§; Rafael Melgares, MD‖‖; Angel Cequier, MD¶¶; Antonio Dominguez, MD##; Vicente Mainar, MD∗∗∗; José R. López-Mínguez, MD†††; José Moreu, MD‡‡‡; Vicens Martí, MD§§§; Raúl Moreno, MD‖‖‖; Pilar Jiménez-Quevedo, MD†; Nieves Gonzalo, MD†; Cristina Fernández, MD†; Carlos Macaya, MD†

Objectives: This study sought to compare the efficacy of drug-eluting balloons (DEB) with that of everolimus-eluting stents (EES) in patients with bare-metal stents (BMS) in-stent restenosis (ISR).